Trial
NCT01565148
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Johns Hopkins University
Collaborators
Juvenile Diabetes Research Foundation; iCo Therapeutics Inc.
Condition
Diabetic Macular Edema
Intervention
iCo-007 350 mcg
Why stopped
Patient's disease progressed and Vision Dropped which led to exit from the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-08-30